Shots:
- The collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines against SARS-CoV-2 variants. CureVac is expected to supply 50M doses of variant vaccines to the UK, following the regulatory approval
- The VTF and the CureVac will deploy mRNA platform to assess multiple SARS-CoV-2 variants and are expected to generate vaccine candidates against selected ones
- Additionally, CureVac will transfer its technology to enable the manufacturing of clinical & commercial quantities of any vaccines that result from the collaboration, as well as manufacturing of CureVac’s existing vaccine against SARS-CoV-2 (CVnCoV), currently in P-III study
Click here to read full press release/ article | Ref: CureVAc | Image: CureVAc
The post CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants first appeared on PharmaShots.
